ArticleBlood2026

Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Vanessa E Kennedy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.